Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2024
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trialD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|March 20, 2025
Molecular tumour board in gastrointestinal cancersL Boscolo Bielo, E Crimini, M Repetto, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancerV De Falco, P P Vitiello, D Ciardiello, et al.
ESMO Open|April 29, 2023
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancerG Martini, V Belli, S Napolitano, et al.
ESMO Open|August 22, 2022
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)D Ciardiello, C Chiarazzo, V Famiglietti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2025
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trialD Ciardiello, G Martini, L Boscolo Bielo, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM studyD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|June 24, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trialD Ciardiello, L Boscolo Bielo, F Pietrantonio, et al.
ESMO Open|March 19, 2025
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trialD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapyL Boscolo Bielo, S Napolitano, A Avallone, et al.
Pageof 2